{"id":510035,"date":"2021-07-06T19:04:07","date_gmt":"2021-07-06T23:04:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/"},"modified":"2021-07-06T19:04:07","modified_gmt":"2021-07-06T23:04:07","slug":"nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/","title":{"rendered":"NVIDIA Launches UK\u2019s Most Powerful Supercomputer,\u00a0for Research in AI and Healthcare"},"content":{"rendered":"<h2>\nOne of World\u2019s Fastest AI Supercomputers to Enable UK Researchers in Digital Biology, Genomics, Quantum Computing and AI; Five Launch Partners Kicking Off Projects<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">LONDON, July  06, 2021  (GLOBE NEWSWIRE) &#8212; NVIDIA today officially launched Cambridge-1, the United Kingdom\u2019s most powerful supercomputer, which will enable top scientists and healthcare experts to use the powerful combination of AI and simulation to accelerate the digital biology revolution and bolster the country\u2019s world-leading life sciences industry.<\/p>\n<p>Dedicated to advancing healthcare, Cambridge-1 represents a $100 million investment by NVIDIA. Its first projects with AstraZeneca, GSK, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, King\u2019s College London and Oxford Nanopore Technologies include developing a deeper understanding of brain diseases like dementia, using AI to design new drugs and improving the accuracy of finding disease-causing variations in human genomes.<\/p>\n<p>Cambridge-1 brings together decades of NVIDIA\u2019s work in accelerated computing, AI and life sciences, where <a href=\"https:\/\/developer.nvidia.com\/clara\" rel=\"nofollow noopener\" target=\"_blank\"><u>NVIDIA Clara<\/u><\/a>\u2122 and AI frameworks are optimized to take advantage of the entire system for large-scale research. An <a href=\"https:\/\/www.nvidia.com\/en-us\/data-center\/dgx-superpod\/\" rel=\"nofollow noopener\" target=\"_blank\"><u>NVIDIA DGX SuperPOD<\/u><\/a>\u2122 supercomputing cluster, it ranks among the world\u2019s top 50 fastest computers and is powered by 100 percent renewable energy.<\/p>\n<p>\u201cCambridge-1 will empower world-leading researchers in business and academia with the ability to perform their life\u2019s work on the U.K.\u2019s most powerful supercomputer, unlocking clues to disease and treatments at a scale and speed previously impossible in the U.K.,\u201d said Jensen Huang, founder and CEO of NVIDIA. \u201cThe discoveries developed on Cambridge-1 will take shape in the U.K., but the impact will be global, driving groundbreaking research that has the potential to benefit millions around the world.\u201d<\/p>\n<p>Cambridge-1 builds on the U.K.\u2019s status as a global leader in life sciences, technology and AI by providing advanced infrastructure for current and future generations to carry out groundbreaking research within the country.<\/p>\n<p>According to a report by Frontier Economics, an economics consulting firm, Cambridge-1 has the potential to create an estimated value of \u00a3600 million (about $825 million) over the next 10 years.<\/p>\n<p>\n        <strong>AstraZeneca: <\/strong><br \/>\n        <strong>Transforming Drug Discovery with AI <\/strong><br \/>\n        <br \/>NVIDIA is collaborating with AstraZeneca to fuel faster drug discoveries by creating a transformer-based generative AI model for chemical structures. Transformer-based neural network architectures, which have become available only in the last several years, allow researchers to leverage massive datasets using self-supervised training methods, avoiding the need for manually labeled examples during pre-training.<\/p>\n<p>The MegaMolBART drug discovery model is being used in reaction prediction, molecular optimization and de novo molecular generation and will optimize the drug development process. It is based on AstraZeneca\u2019s MolBART transformer model and is being trained on the ZINC chemical compound database \u2014 using NVIDIA\u2019s Megatron framework to enable massively scaled-out training on supercomputing infrastructure. This open-source model will be available to researchers and developers in the <a href=\"https:\/\/ngc.nvidia.com\/catalog\" rel=\"nofollow noopener\" target=\"_blank\"><u>NVIDIA NGC\u2122 software catalog<\/u><\/a>.<\/p>\n<p>NVIDIA and AstraZeneca have a separate project on Cambridge-1 focused on the use of AI in digital pathology. In digital pathology, significant time and money are spent annotating whole slide images of tissue samples, to aid the search for new insights. By using unsupervised AI algorithms trained on thousands of images, it is possible to remove the process of annotating while simultaneously finding potential imaging features that correlate with drug response.<\/p>\n<p>\u201cTraining AI algorithms on whole slide images is challenging in part due to the size of the images,\u201d said Lindsay Edwards, vice president of Data Science and AI, Respiratory and Immunology, BioPharmaceuticals R&amp;D at AstraZeneca. \u201cWorking with NVIDIA on Cambridge-1 enables us to scale our current work and develop new methodologies advancing the use of AI in digital pathology.\u201d<\/p>\n<p>\n        <strong>GSK: Steering Great Science with Partners for Patients<\/strong><br \/>\n        <br \/>GSK\u2019s research and development approach includes a focus on genetically validated targets, which are twice as likely to become medicines and now make up more than 70 percent of its research pipeline. To maximize the potential of these insights, GSK has built state-of-the-art capabilities at the intersection of human genetics, functional genomics, and artificial intelligence and machine learning.<\/p>\n<p>\u201cAdvanced technologies are core to GSK\u2019s R&amp;D approach and help to unlock the potential of large, complex data through predictive modeling at new levels of speed, precision and scale,\u201d said Dr. Kim Branson, senior vice president and global head of AI-ML at GSK. \u201cWe are pleased to have the opportunity to partner with NVIDIA to deliver on GSK\u2019s drug discovery ambition and contribute to the U.K.\u2019s rich life sciences ecosystem \u2014 both aims that have patient benefit at the centre.\u201d<\/p>\n<p>Working with partners at the cutting edge of genetics, genomics and AI\/ML can ultimately help GSK predict more about human health, and develop better medicines that are twice as likely to succeed in the clinic and go on to become approved therapies that benefit patients. Access to Cambridge-1 will contribute additional computational power and state-of-the-art AI technology to GSK\u2019s drug discovery process.<\/p>\n<p>\n        <strong>King\u2019s College London &amp; Guy\u2019s and St Thomas\u2019 NHS Foundation Trust: AI-Generated Synthetic Brain Data <\/strong><br \/>\n        <br \/>King\u2019s College London and Guy\u2019s and St Thomas\u2019 NHS Foundation Trust are using Cambridge-1 to teach AI models to generate synthetic brain images by learning from tens of thousands of MRI brain scans, from various ages and diseases. The ultimate goal is to use this synthetic data model to gain a better understanding of diseases like dementia, stroke, brain cancer and multiple sclerosis and enable earlier diagnosis and treatment.<\/p>\n<p>As this AI synthetic brain model can generate an infinite amount of never-seen brain images with chosen characteristics (age, disease, etc.), it will allow a better and more nuanced understanding of what diseases look like, possibly enabling an earlier and more accurate diagnosis.<\/p>\n<p>\u201cThrough this partnership, we will be able to use a scale of computational power that is unprecedented in healthcare research,\u201d said Professor Sebastien Ourselin, head of the School of Biomedical Engineering &amp; Imaging Sciences at King\u2019s College London. \u201cIt will be truly transformational for the health and treatment of patients.\u201d<\/p>\n<p>This research leverages several of the U.K.\u2019s world-leading healthcare resources through close collaboration with the National Health Service and the UK Biobank, one of the richest biomedical databases in the world. King\u2019s College London intends to share this synthetic data model with the greater research and startup community.<\/p>\n<p>\u201cThe power of artificial intelligence in healthcare will help to speed up diagnosis for patients, improve services such as breast cancer screening, and support the way that we risk assess and prioritize patients according to clinical need,\u201d said Professor Ian Abbs, chief executive officer of Guy\u2019s and St Thomas\u2019 NHS Foundation Trust. \u201cWe are excited about our involvement in the Cambridge-1 data center as it will enable us to be amongst the first to benefit from these new AI capabilities \u2014 using the very latest technology to benefit our patients, as well as manage precious resources more efficiently.\u201d<\/p>\n<p>\n        <strong>Oxford Nanopore: Scalable, Real-Time Genomics<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/nanoporetech.com\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <u>Oxford Nanopore Technologies\u2019<\/u><br \/>\n        <\/a> long-read sequencing technology is being used in more than 100 countries to gain genomic insights across a breadth of research areas \u2014 from human and plant health to environmental monitoring and antimicrobial resistance.<\/p>\n<p>Oxford Nanopore deploys NVIDIA technology in a variety of genomic sequencing platforms to develop AI tools that improve the speed and accuracy of genomic analysis. With access to Cambridge-1, Oxford Nanopore will be able to carry out tasks relating to algorithm improvement in hours rather than days. These improved algorithms will ensure improved genomic accuracy for greater insights and quicker turnaround times in scientists\u2019 hands.<\/p>\n<p>\u201cHarnessing the power of Cambridge-1 will help us further speed up our algorithm development to support powerful, accurate genomic analysis,\u201d said Rosemary Sinclair Dokos, vice president of Product and Programme Management at Oxford Nanopore. \u201cThis will in turn enable the scientists using our technology on the ground to gain more insights than ever before, across a breadth of research areas.\u201d<\/p>\n<p>\n        <strong>About Cambridge-1<\/strong><br \/>\n        <br \/>Cambridge-1 is the first NVIDIA supercomputer designed and built for external research access. The company will collaborate with researchers to make much of this work available to the greater scientific community.<\/p>\n<p>Featuring 80 <a href=\"https:\/\/www.nvidia.com\/en-us\/data-center\/dgx-a100\/\" rel=\"nofollow noopener\" target=\"_blank\"><u>DGX\u2122 A100<\/u><\/a> systems integrating <a href=\"https:\/\/www.nvidia.com\/en-us\/data-center\/a100\/\" rel=\"nofollow noopener\" target=\"_blank\"><u>NVIDIA A100 GPUs<\/u><\/a>, <a href=\"https:\/\/www.nvidia.com\/en-us\/networking\/products\/data-processing-unit\/\" rel=\"nofollow noopener\" target=\"_blank\"><u>BlueField\u00ae-2 DPUs<\/u><\/a> and <a href=\"https:\/\/www.nvidia.com\/en-us\/networking\/products\/infiniband\/\" rel=\"nofollow noopener\" target=\"_blank\"><u>NVIDIA HDR InfiniBand<\/u><\/a> networking, Cambridge-1 is an <a href=\"https:\/\/www.nvidia.com\/en-us\/data-center\/dgx-superpod\/\" rel=\"nofollow noopener\" target=\"_blank\"><u>NVIDIA DGX SuperPOD<\/u><\/a> that delivers more than 400 petaflops of AI performance and 8 petaflops of Linpack performance. The system is located at a facility operated by NVIDIA partner Kao Data.<\/p>\n<p>Cambridge-1 is the first supercomputer NVIDIA has dedicated to advancing industry-specific research in the U.K. The company also intends to build an AI Center for Excellence in Cambridge featuring a new Arm-based supercomputer, which will support more industries across the country.<\/p>\n<p>Watch the <a href=\"https:\/\/www.youtube.com\/watch?v=LKa-kDYZ1A8\" rel=\"nofollow noopener\" target=\"_blank\"><u>inauguration<\/u><\/a> event and learn more about the <a href=\"https:\/\/www.nvidia.com\/en-us\/industries\/healthcare-life-sciences\/cambridge-1\/\" rel=\"nofollow noopener\" target=\"_blank\"><u>Cambridge-1 supercomputer.<\/u><\/a><\/p>\n<p>\n        <strong>About NVIDIA<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.nvidia.com\/#source=pr\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <u>NVIDIA<\/u><br \/>\n        <\/a>\u2019s (NASDAQ: NVDA) invention of the GPU in 1999 sparked the growth of the PC gaming market and has redefined modern computer graphics, high performance computing and artificial intelligence. The company\u2019s pioneering work in accelerated computing and AI is reshaping trillion-dollar industries, such as transportation, healthcare and manufacturing, and fueling the growth of many others. More information at <a href=\"https:\/\/nvidianews.nvidia.com\/\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/nvidianews.nvidia.com\/<\/u><\/a>.<\/p>\n<p align=\"left\">\n        <strong>For further information, contact:<\/strong><br \/>\n        <br \/>Janette Ciborowski<br \/>NVIDIA Corporation<br \/>+1-734-330-8817<br \/><a href=\"mailto:jciborowski@nvidia.com\" rel=\"nofollow noopener\" target=\"_blank\"><u>jciborowski@nvidia.com<\/u><\/a><\/p>\n<p>Certain statements in this press release including, but not limited to, statements as to: the benefits, impact, performance, features, and availability of our products and services; Cambridge-1 enabling top scientists and healthcare experts to accelerate the digital biology revolution and bolster the U.K.\u2019s world-leading life sciences industry; the details and impact of NVIDIA\u2019s collaborations with partners including AstraZeneca, GSK, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, King\u2019s College London, and Oxford Nanopore; Cambridge-1\u2019s potential economic value created; the AI synthetic brain model taught by Cambridge-1 allowing a better and more nuanced understanding of what diseases look like, possibly enabling an earlier and more accurate diagnosis; King\u2019s College London\u2019s intent to share synthetic data model with the greater research and startup community; transformer-based neural network architectures allowing researchers to leverage massive datasets; and access to Cambridge-1 contributing additional computational power and state-of-the-art AI technology to GSK\u2019s drug discovery process are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic conditions; our reliance on third parties to manufacture, assemble, package and test our products; the impact of technological development and competition; development of new products and technologies or enhancements to our existing product and technologies; market acceptance of our products or our partners&#8217; products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of our products or technologies when integrated into systems; as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company&#8217;s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.<\/p>\n<p>\u00a9 2021 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, BlueField, DGX, NGC, NVIDIA Clara, and NVIDIA DGX SuperPOD are trademarks and\/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. All other trademarks and copyrights are the property of their respective owners. Features, pricing, availability and specifications are subject to change without notice.\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjA5MCM0Mjg1MDgwIzIwMDY5MTI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/6543b034-5845-4bcb-aa63-4b4bcdc8ba7a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>One of World\u2019s Fastest AI Supercomputers to Enable UK Researchers in Digital Biology, Genomics, Quantum Computing and AI; Five Launch Partners Kicking Off Projects LONDON, July 06, 2021 (GLOBE NEWSWIRE) &#8212; NVIDIA today officially launched Cambridge-1, the United Kingdom\u2019s most powerful supercomputer, which will enable top scientists and healthcare experts to use the powerful combination of AI and simulation to accelerate the digital biology revolution and bolster the country\u2019s world-leading life sciences industry. Dedicated to advancing healthcare, Cambridge-1 represents a $100 million investment by NVIDIA. Its first projects with AstraZeneca, GSK, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, King\u2019s College London and Oxford Nanopore Technologies include developing a deeper understanding of brain diseases like dementia, using AI to design new &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NVIDIA Launches UK\u2019s Most Powerful Supercomputer,\u00a0for Research in AI and Healthcare&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-510035","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NVIDIA Launches UK\u2019s Most Powerful Supercomputer,\u00a0for Research in AI and Healthcare - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NVIDIA Launches UK\u2019s Most Powerful Supercomputer,\u00a0for Research in AI and Healthcare - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"One of World\u2019s Fastest AI Supercomputers to Enable UK Researchers in Digital Biology, Genomics, Quantum Computing and AI; Five Launch Partners Kicking Off Projects LONDON, July 06, 2021 (GLOBE NEWSWIRE) &#8212; NVIDIA today officially launched Cambridge-1, the United Kingdom\u2019s most powerful supercomputer, which will enable top scientists and healthcare experts to use the powerful combination of AI and simulation to accelerate the digital biology revolution and bolster the country\u2019s world-leading life sciences industry. Dedicated to advancing healthcare, Cambridge-1 represents a $100 million investment by NVIDIA. Its first projects with AstraZeneca, GSK, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, King\u2019s College London and Oxford Nanopore Technologies include developing a deeper understanding of brain diseases like dementia, using AI to design new &hellip; Continue reading &quot;NVIDIA Launches UK\u2019s Most Powerful Supercomputer,\u00a0for Research in AI and Healthcare&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-06T23:04:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjA5MCM0Mjg1MDgwIzIwMDY5MTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NVIDIA Launches UK\u2019s Most Powerful Supercomputer,\u00a0for Research in AI and Healthcare\",\"datePublished\":\"2021-07-06T23:04:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\\\/\"},\"wordCount\":1955,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjA5MCM0Mjg1MDgwIzIwMDY5MTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\\\/\",\"name\":\"NVIDIA Launches UK\u2019s Most Powerful Supercomputer,\u00a0for Research in AI and Healthcare - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjA5MCM0Mjg1MDgwIzIwMDY5MTI=\",\"datePublished\":\"2021-07-06T23:04:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjA5MCM0Mjg1MDgwIzIwMDY5MTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjA5MCM0Mjg1MDgwIzIwMDY5MTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NVIDIA Launches UK\u2019s Most Powerful Supercomputer,\u00a0for Research in AI and Healthcare\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NVIDIA Launches UK\u2019s Most Powerful Supercomputer,\u00a0for Research in AI and Healthcare - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/","og_locale":"en_US","og_type":"article","og_title":"NVIDIA Launches UK\u2019s Most Powerful Supercomputer,\u00a0for Research in AI and Healthcare - Market Newsdesk","og_description":"One of World\u2019s Fastest AI Supercomputers to Enable UK Researchers in Digital Biology, Genomics, Quantum Computing and AI; Five Launch Partners Kicking Off Projects LONDON, July 06, 2021 (GLOBE NEWSWIRE) &#8212; NVIDIA today officially launched Cambridge-1, the United Kingdom\u2019s most powerful supercomputer, which will enable top scientists and healthcare experts to use the powerful combination of AI and simulation to accelerate the digital biology revolution and bolster the country\u2019s world-leading life sciences industry. Dedicated to advancing healthcare, Cambridge-1 represents a $100 million investment by NVIDIA. Its first projects with AstraZeneca, GSK, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, King\u2019s College London and Oxford Nanopore Technologies include developing a deeper understanding of brain diseases like dementia, using AI to design new &hellip; Continue reading \"NVIDIA Launches UK\u2019s Most Powerful Supercomputer,\u00a0for Research in AI and Healthcare\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-06T23:04:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjA5MCM0Mjg1MDgwIzIwMDY5MTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NVIDIA Launches UK\u2019s Most Powerful Supercomputer,\u00a0for Research in AI and Healthcare","datePublished":"2021-07-06T23:04:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/"},"wordCount":1955,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjA5MCM0Mjg1MDgwIzIwMDY5MTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/","name":"NVIDIA Launches UK\u2019s Most Powerful Supercomputer,\u00a0for Research in AI and Healthcare - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjA5MCM0Mjg1MDgwIzIwMDY5MTI=","datePublished":"2021-07-06T23:04:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjA5MCM0Mjg1MDgwIzIwMDY5MTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjA5MCM0Mjg1MDgwIzIwMDY5MTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nvidia-launches-uks-most-powerful-supercomputer-for-research-in-ai-and-healthcare\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NVIDIA Launches UK\u2019s Most Powerful Supercomputer,\u00a0for Research in AI and Healthcare"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510035","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=510035"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510035\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=510035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=510035"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=510035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}